dr reddy's glp-1 drugs portfolio 2025 With the launch of our oral semaglutide biosimilar, Obeda® tablets, we are broadening our GLP‑1 to offer more choice and flexibility for patients. Oral semaglutide, as a convenient and flexible option How to Invest in GLP-1

Repositioning of the global epicentre of non-optimal cholesterol

An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition

Originally designed to treat type 2 diabetes, these medications are now approved for weight management due to their impressive results in promoting healthy, sustainable weight loss

Reputable practices distinguish themselves through transparency about product sourcing, honest discussions about realistic outcomes, and a commitment to ongoing patient monitoring and follow-up care

SUMO proteins can conjugate to substrate proteins in similar to ubiquitin

Current Protein & Peptide Science